Quidel Corporation (QDEL) News
Filter QDEL News Items
QDEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
QDEL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest QDEL News From Around the Web
Below are the latest news stories about QUIDELORTHO CORP that investors may wish to consider to help them evaluate QDEL as an investment opportunity.
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business UpdatesPreliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024 Scott Huennekens Appointed to NeuroPace Board of Directors effective January 6th Management presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th Company to host an Investor Day on January 28th in New York City MOUNTAIN VIEW, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical dev |
QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, December 31, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. |
Does QuidelOrtho Corporation (QDEL) Have Healthy Long-Term Growth Prospects?Invesco Distributors, Inc., an investment management firm, released its “Invesco Small Cap Value Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund underperformed the benchmark due to stock selection and an overweight in industrials. A lack of exposure to real estate also detracted […] |
Insider Buying: QuidelOrtho President Bought US$250k Of SharesInvestors who take an interest in QuidelOrtho Corporation ( NASDAQ:QDEL ) should definitely note that the President... |
QuidelOrtho Announces Appointment of Two Independent Directors to its BoardSAN DIEGO, December 10, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. |
QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle GroupSAN DIEGO, November 20, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the pricing of the previously announced underwritten secondary offering (the "Offering") by Carlyle Partners VI Cayman Holdings, L.P. (the "Selling Stockholder") of 8,260,183 shares of the Company’s common stock ("Common Stock"). |
QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle GroupSAN DIEGO, November 19, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the "Offering") by Carlyle Partners VI Cayman Holdings, L.P. (the "Selling Stockholder") of 8,260,183 shares of the Company’s common stock ("Common Stock"). |
QuidelOrtho Third Quarter 2024 Earnings: Beats ExpectationsQuidelOrtho ( NASDAQ:QDEL ) Third Quarter 2024 Results Key Financial Results Revenue: US$727.1m (down 2.3% from 3Q... |
QuidelOrtho Corp (QDEL) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive Growth ...QuidelOrtho Corp (QDEL) reports solid progress in business improvements despite revenue decline and external headwinds. |
QuidelOrtho Reports Third Quarter 2024 Financial ResultsSAN DIEGO, November 07, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the third quarter ended September 29, 2024. |